Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 57.43% is 78% above its 5-year average of 32.28%, near the high end of its 5-year range (-65.52%–100.00%).
249.90% above its 12-month average of 16.41%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 0.00%.
GROSS MARGIN
57.43%
GROSS MARGIN AVG TTM
16.41%
GROSS MARGIN AVG 3Y
57.18%
GROSS MARGIN AVG 5Y
32.28%
GROSS MARGIN AVG 10Y
N/A
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+249.90%
CURRENT VS 3Y AVG
+0.44%
CURRENT VS 5Y AVG
+77.93%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
40.63%
median of 726 covered companies
CURRENT VS SECTOR MEDIAN
+41.35%
vs the sector median at left
Market Cap
$1.91B
Gross Margin
70.49%
TTM Avg
67.64%
3Y Avg
66.50%
5Y Avg
65.90%
Market Cap
$1.89B
Gross Margin
78.67%
TTM Avg
83.63%
3Y Avg
79.97%
5Y Avg
53.31%
Market Cap
$1.89B
Gross Margin
64.48%
TTM Avg
64.91%
3Y Avg
63.02%
5Y Avg
55.66%
Market Cap
$1.85B
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
22.32%
5Y Avg
30.29%
Market Cap
$2.00B
Gross Margin
86.13%
TTM Avg
85.03%
3Y Avg
84.60%
5Y Avg
84.81%
Market Cap
$2.01B
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Immunome, Inc. (IMNM) | $1.93B | 57.43% | 16.41% | 57.18% | 32.28% |
| Establishment Labs Holdings Inc. (ESTA)vs › | $1.91B | 70.49% | 67.64% | 66.50% | 65.90% |
| AxoGen, Inc. (AXGN)vs › | $1.95B | 74.56% | 75.05% | 76.31% | 78.00% |
| Agios Pharmaceuticals, Inc. (AGIO)vs › | $1.89B | 78.67% | 83.63% | 79.97% | 53.31% |
| BioLife Solutions, Inc. (BLFS)vs › | $1.89B | 64.48% | 64.91% | 63.02% | 55.66% |
| Palvella Therapeutics, Inc. (PVLA)vs › | $1.85B | 0.00% | 0.00% | 22.32% | 30.29% |
| Inspire Medical Systems, Inc. (INSP)vs › | $2.00B | 86.13% | 85.03% | 84.60% | 84.81% |
| Mineralys Therapeutics, Inc. (MLYS)vs › | $2.01B | 0.00% | 0.00% | 0.00% | 0.00% |
| Novavax, Inc. (NVAX)vs › | $1.83B | 93.67% | 81.97% | 61.43% | 74.28% |
| Azenta, Inc. (AZTA)vs › | $1.85B | 44.05% | 44.96% | 41.63% | 40.93% |
Gross Margin
57.4%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 0.00% |
| 2026-03-31 | 0.00% |
| 2025-12-31 | 0.00% |
| 2025-09-30 | 0.00% |
| 2025-06-30 | 82.07% |
| 2025-03-31 | 100.00% |
| 2024-12-31 | 100.00% |
| 2024-09-30 | 100.00% |
| 2024-06-30 | 100.00% |
| 2024-03-31 | 100.00% |
| 2023-12-31 | 100.00% |
| 2023-09-30 | 95.34% |
| 2023-06-30 | -34.08% |
| 2023-03-31 | -65.52% |
| 2022-12-31 | 0.00% |
| 2022-09-30 | 0.00% |
| 2022-06-30 | 0.00% |
| 2022-03-31 | 0.00% |
| 2021-12-31 | 0.00% |
| 2021-09-30 | 0.00% |
| 2021-06-30 | 0.00% |
| 2021-03-31 | 0.00% |
| 2020-12-31 | 0.00% |
| 2020-09-30 | 0.00% |
| 2020-06-30 | 0.00% |
| 2020-03-31 | 0.00% |
| 2019-12-31 | 0.00% |
| 2019-09-30 | 0.00% |
| 2019-06-30 | 0.00% |
| 2019-03-31 | 0.00% |
